Current role of biomarkers in the initiation and weaning of kidney replacement therapy in acute kidney injury

Table 3 Summary of studies on role of biomarkers for weaning of KRT

Ref.	Biomarker studied	Type of study	No. of patients	AUROC (95%CI)	Cutoff	Sensitivity (95%CI)	Specificity (95%CI)
Chen et al[52]	SNGAL	Prospective	110	0.81	403	91	61
Chen et al[52]	SNGAL	All AKI, prospective nonseptic AKI	70	0.89	403	81	89
Chen et al[52]	SNGAL	Prospective and septic AKI	40	0.65	782	63	67
Komaru et al[53]	UNGAL	Prospective	105	0.81 (0.71-0.88)	186	94	60
Kim et al[54]	SNGAL	Prospective	110	0.654 (0.539-0.768)	-	90.5	44.9
von Groote et al[55]	PenKid–pre-KRT	Post hoc analysis	210	0.582 (0.505–0.660)	95.25	50	67
von Groote et al[55]	PenKid at day 10	Post hoc analysis	210	0.681 (0.594–0.767)	77.1	60	71
von Groote et al[55]	PenKid at day 28	Post hoc analysis	210	0.660 (0.570–0.750)	74.9	52	75
Kim et al[54]	Serum CyC	Prospective	110	0.739 (0.624-0.853)	-	76.2	62.9
Yang et al[56]	Serum CyC	Prospective	69	0.525 (0.408-0.643)	-	-	-
Aregger et al[57]	Kynurenic acid on day 1	Prospective	92	0.72 (0.59-0.85)	-	-	-
Aregger et al[57]	Kynurenic acid on day 2	Prospective	92	0.80 (0.69-0.93)	-	-	-
Aregger et al[57]	Kynurenic acid on day 3	Prospective	92	0.78 (0.66-0.90)	-	-	-
Pan et al[58]	Liver-fatty acid-binding proteins/creatinine	Prospective	140	0.79	-	-	-

AUROC: Area under the receiver operating characteristic curve; CI: Confidence interval; KRT: Kidney replacement therapy; SNGAL: Serum neutrophil gelatinase-associated lipocalin; AKI: Acute kidney injury; UNGAL: Urinary neutrophil gelatinase-associated lipocalin; CyC: Cystatin C; PenKid: Proenkephalin 119–159